Kesimpta (ofatumumab) for the Treatment of Relapsing Multiple Sclerosis (RMS)
Kesimpta is the first and only self-administered, targeted B-cell therapy for RMS. Credit: Novartis Pharma AG.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more